{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.3"},{"groupId":"OG001","value":"41.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"155"},{"groupId":"OG001","value":"156"}],"units":"Participants"}],"title":"C5D1 (>=3 pt increase)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.9"},{"groupId":"OG001","value":"47.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"119"}],"units":"Participants"}],"title":"FUM6 (>=3 pt increase)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.7"},{"groupId":"OG001","value":"46.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"99"}],"units":"Participants"}],"title":"FUM12 (>=3 pt increase)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.6"},{"groupId":"OG001","value":"53.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"83"}],"units":"Participants"}],"title":"FUM18 (>=3 pt increase)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.3"},{"groupId":"OG001","value":"50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"74"}],"units":"Participants"}],"title":"FUM24 (>=3 pt increase)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.0"},{"groupId":"OG001","value":"57.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"64"}],"units":"Participants"}],"title":"Ext FUM6 (>=3 pt increase)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.1"},{"groupId":"OG001","value":"34.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"156"},{"groupId":"OG001","value":"157"}],"units":"Participants"}],"title":"C5D1 (>=6 pt increase)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.5"},{"groupId":"OG001","value":"43.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"119"}],"units":"Participants"}],"title":"FUM6 (>=6 pt increase)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.2"},{"groupId":"OG001","value":"47.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"100"}],"units":"Participants"}],"title":"FUM12 (>=6 pt increase)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.9"},{"groupId":"OG001","value":"51.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"83"}],"units":"Participants"}],"title":"FUM18 (>=6 pt increase)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.5"},{"groupId":"OG001","value":"48.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"75"}],"units":"Participants"}],"title":"FUM24 (>=6 pt increase)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"56.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"65"}],"units":"Participants"}],"title":"Ext FUM6 (>=6 pt increase)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.4"},{"groupId":"OG001","value":"28.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"156"},{"groupId":"OG001","value":"157"}],"units":"Participants"}],"title":"C5D1 (>=7 pt increase)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.1"},{"groupId":"OG001","value":"40.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"119"}],"units":"Participants"}],"title":"FUM6 (>=7 pt increase)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.1"},{"groupId":"OG001","value":"45.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"100"}],"units":"Participants"}],"title":"FUM12 (>=7 pt increase)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.1"},{"groupId":"OG001","value":"43.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"83"}],"units":"Participants"}],"title":"FUM18 (>=7 pt increase)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.6"},{"groupId":"OG001","value":"42.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"75"}],"units":"Participants"}],"title":"FUM24 (>=7 pt increase)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"47.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"65"}],"units":"Participants"}],"title":"Ext FUM6 (>=7 pt increase)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"204"}],"units":"Participants"}],"description":"FACT-Lym: 42-items in 5 subscales. Responses to each item range from 0 (Not at all) to 4 (Very much). FACT-Lym Lymphoma subscale includes 15 items (total score range = 0-60). FACT-Lym TOI is sum of 3 subscales (physical well-being, functional well-being, lymphoma subscale) and includes 29 items (total score range = 0-116). FACT-Lym total score is sum of 42 items (total score ranges from 0-168). For all above, higher scores indicate a better PRO/QoL. DI from baseline: at least 3 point increase from baseline in FACT-Lym Lymphoma subscale; at least 6 point increase from baseline in FACT Lym TOI; at least 7 point increase from baseline in FACT Lym total scores. In timeframe, follow-up months represents months after EOI (e.g. Follow-up Month 2 is 2 months after EOI; EOI = up to Month 6).","groups":[{"description":"Participants received Bendamustine 120 mg/m\\^2 IV infusion on Days 1 and 2 of each 28-day cycle for up to six cycles.","id":"OG000","title":"Bendamustine Alone"},{"description":"Induction phase: Participants received Bendamustine 90 mg/m\\^2 IV on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of Cycles 2-6 (28-day cycles) for the first 10 participants and on Days 1 and 2 of each 28-day cycle for Cycles 1-6 for remaining participants. Participants also received obinutuzumab 1000 mg IV infusion on Days 1, 8, and 15 of Cycle 1; Day 1 of Cycles 2-6. Maintenance phase: Participants with CR, PR or SD then received obinutuzumab 1000 mg IV infusion every 2 months until disease progression or for up to 2 years (whichever occurred first).","id":"OG001","title":"Obinutuzumab + Bendamustine"}],"paramType":"NUMBER","populationDescription":"ITT population. Here, number of participants analyzed signified those participants who were evaluable for this outcome.","reportingStatus":"POSTED","timeFrame":"Baseline, Cycle 5 Day 1 (C5D1) (Cycle length = 28 days), Follow-up Months 6 (FUM6), 12 (FUM12), 18 (FUM18), 24 (FUM24), Extension Follow Up Month 6 (Extension FUM6)","title":"Percentage of Participants With Definitive Improvement (DI) From Baseline in FACT-Lym Instrument Scores","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}